EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 359 filers reported holding EXELIXIS INC in Q1 2023. The put-call ratio across all filers is 0.23 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,913,961 | +7.2% | 2,375,925 | -6.2% | 0.84% | +21.0% |
| Q2 2023 | $48,424,740 | -4.4% | 2,534,000 | -2.9% | 0.69% | -6.0% |
| Q1 2023 | $50,640,690 | +18.1% | 2,609,000 | -2.4% | 0.74% | +29.2% |
| Q4 2022 | $42,882,940 | +2.3% | 2,673,500 | 0.0% | 0.57% | -5.5% |
| Q3 2022 | $41,921,000 | -24.8% | 2,673,500 | -0.2% | 0.60% | -23.6% |
| Q2 2022 | $55,767,000 | -9.5% | 2,678,500 | -1.5% | 0.79% | +10.1% |
| Q1 2022 | $61,640,000 | +17.9% | 2,719,000 | -4.9% | 0.72% | +32.8% |
| Q4 2021 | $52,263,000 | -13.5% | 2,859,000 | 0.0% | 0.54% | -12.1% |
| Q3 2021 | $60,439,000 | +13.1% | 2,859,000 | -2.5% | 0.61% | +17.7% |
| Q2 2021 | $53,421,000 | -19.7% | 2,932,000 | -0.4% | 0.52% | -26.0% |
| Q1 2021 | $66,517,000 | +12.6% | 2,944,500 | 0.0% | 0.70% | +4.0% |
| Q4 2020 | $59,096,000 | -21.4% | 2,944,500 | -4.2% | 0.68% | -34.8% |
| Q3 2020 | $75,147,000 | +3.9% | 3,073,500 | +0.9% | 1.04% | +1.4% |
| Q2 2020 | $72,348,000 | +5.7% | 3,047,500 | -23.3% | 1.02% | -22.9% |
| Q1 2020 | $68,457,000 | -1.2% | 3,975,400 | +1.1% | 1.33% | +20.9% |
| Q4 2019 | $69,259,000 | +1.5% | 3,930,700 | +1.9% | 1.10% | -13.5% |
| Q3 2019 | $68,241,000 | -17.7% | 3,858,700 | -0.5% | 1.27% | -10.3% |
| Q2 2019 | $82,890,000 | +2378.8% | 3,878,800 | +2660.7% | 1.42% | +669.0% |
| Q1 2019 | $3,344,000 | +80.9% | 140,500 | +49.5% | 0.18% | +50.8% |
| Q4 2018 | $1,849,000 | +67.6% | 94,000 | +88.8% | 0.12% | +11.9% |
| Q1 2018 | $1,103,000 | -28.3% | 49,800 | -1.6% | 0.11% | -32.3% |
| Q4 2017 | $1,538,000 | +22.1% | 50,600 | -2.7% | 0.16% | +22.0% |
| Q3 2017 | $1,260,000 | -1.6% | 52,000 | 0.0% | 0.13% | -12.6% |
| Q2 2017 | $1,281,000 | +13.7% | 52,000 | 0.0% | 0.15% | +0.7% |
| Q1 2017 | $1,127,000 | +25.9% | 52,000 | -13.3% | 0.15% | -18.0% |
| Q4 2016 | $895,000 | +16.7% | 60,000 | 0.0% | 0.18% | +31.7% |
| Q3 2016 | $767,000 | -42.2% | 60,000 | -64.7% | 0.14% | -44.4% |
| Q2 2016 | $1,328,000 | +95.3% | 170,000 | 0.0% | 0.25% | +103.3% |
| Q1 2016 | $680,000 | – | 170,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |